Jupiter Neurosciences, Inc. (JUNS) company profile
Close on Nov 17, 2026Market cap $1.17MP/E –Yield –
About Jupiter Neurosciences
Pharmaceutical Preparations, SIC 2834
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company focused on developing treatments that utilize an enhanced oral resveratrol formulation to address neuroinflammation, central nervous system disorders, and rare diseases. Its proprietary platform product, JOTROL, delivers resveratrol using micellar technology designed to enhance absorption and bioavailability. The company operates through two main business segments: pharmaceutical operations targeting therapeutic indications such as Parkinson's disease, and consumer products consisting of premium nutritional supplements sold under the Nugevia brand name. The initial Nugevia wellness product line comprises three formulations—GLO, MND, and PWR—marketed directly to consumers for cellular health, cognitive support, and mitochondrial performance.
The company maintains its principal executive offices and headquarters in Jupiter, Florida. Its product operations serve consumers in the United States with planned international reach, supported by regional business development agreements across Southeast Asia, including China, Malaysia, and Singapore. Clinical trial supplies are manufactured in Florida, with underlying technology developed alongside a partner based in Germany.
Summary of the business section of Jupiter Neurosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Jupiter Neurosciences, Inc.
- Founded
- 2016
- Headquarters
- Jupiter, FL
- Address
- 1001 North Us Hwy 1, Suite 504 33477
- Phone
- (561) 406-6154
- Website
- jupiterneurosciences.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- ASSURANCE DIMENSIONS, LLC, Coral Springs, Florida
Stock & identifiers
- Ticker
- JUNS
- Exchange
- Nasdaq
- IPO date
- Dec 3, 2024
- Shares outstanding
- 1M, Aug 14, 2026
- Public float
- $20.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-75 reverse, Aug 7, 2026
- SEC CIK
- 1679628
- CUSIP
- 48208B302
- ISIN
- US48208B3024
- FIGI
- BBG0130XFNK0
- Share class FIGI
- BBG0130XFPG0
- EIN
- 47-4828381
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marshall A. Hayward | Chief Scientific Officer, Director | 2,995,077 |
| Christer Rosen | CEO and Chairman, Director | 11,078,892 |
| Alison D. Silva | President and COO, Director | 112,777 |
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | 617,411 |
| Saleem Elmasri | Chief Financial Officer | 66,239 |
| Andrew Jon Cutler | Director | – |
| Nicholas H. Hemmerly | Director | 95,550 |
| Julie B. Kampf | Director | 82,875 |
| Holger Weis | Director | 96,581 |
| Tomas Jan Philipson | Director | – |
| Allison W. Brady | Director | 21,750 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Christer Rosén Chairman of the Board and Chief Executive Officer | $441.00K | $210.00K | – | $20.41K | $671.41K | +336% |
| Saleem Elmasri Chief Financial Officer | $240.00K | $72.00K | $102.13K | – | $414.13K | +226% |
| Marshall Hayward Chief Scientific Officer | $176.40K | $50.00K | – | $16.15K | $242.45K | +125% |
| Alexander Rosén Chief Administration Officer | $252.00K | $72.00K | – | $15.67K | $339.67K | +228% |
| Alison Silva Chief Business Officer and President | $315.00K | $45.00K | $255.32K | $16.78K | $632.10K | +356% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of five full-time employees, two full-time consultants, three part-time consultants, and our six Scientific Advisory Board members.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 28, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 1, 2026 | Late filing | Notification of late filing |
| Feb 27, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 14, 2025 | Late filing | Notification of late filing |
| Apr 21, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 4, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 5, 2017 | Name change | Name changed from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc. |
See a number that looks wrong?